Less than 20% of biologic-eligible patients with GINA Step 5 asthma receive biologic therapy. Experts discuss real-world gaps in initiation, access, and adherence affecting patient outcomes.
Key topics include real-world data on biologic initiation, patient cases revealing barriers, and practical methods to assess the burden of severe asthma. The discussion also covers the 'Start, Stay, Sustain' framework for patient-centered care.